Chemical Structure (Tadalafil 1)
Tadalafil Tablet, Film Coated
Product Images NDC 35573-463
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 35573-463). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Burel Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Carton (Tadalafil 10)
5 mg (Tadalafil 11)
This is a description of Tadalafil Tablets, USP, a prescription drug marketed by Burel Pharmaceuticals, LLC. It comes in a package of 30 tablets, each containing Tadalafil USP 5 mg. The usual dosage is not mentioned and instructions are to be found in accompanying literature. It should be stored at 25° (77°F) and kept out of the reach of children. It must be dispensed in a tight container. There is a warning against overdosing and it should not be taken by pregnant women or children. The manufacturing company is VKT Pharma Private Limited in India.*
10 mg (Tadalafil 12)
This is a product description of Tadalafil tablets, USP containing 10mg of Taataaf per film-coated tablet. The usual dosage is to be determined based on accompanying literature. It is advised to store them at the USP controlled room temperature of 25° (77°F), with excursions permitted to 10-15°C (50-59°F). These tablets should be kept out of reach of children and dispensed in the container provided. The manufacturer is VKT Pharma Private Limited, Skl India, and the product is marketed by Burel Pharmaceuticals, LLG in Mason, 0 45040, USA.*
20 mg (Tadalafil 13)
Each film-coated tablet contains Tadalafil for dosage. The tablet comes in a container and a single dosage appears to be 35573-463-30. No further information is available.*
Tadalafil-tablets-figure-1 (Tadalafil 2)
The document seems to be a chart showing the difference in blood pressure between taking Tadalafil and a placebo. It includes measurements for standing and supine systolic and diastolic blood pressure over a certain period of time. No further information is available.*
Tadalafil-tablets-figure-2 (Tadalafil 3)
The given text appears to be a mix of numerals, symbols, and alphabets. The content doesn't form a coherent sentence or description, and thus, it is not possible to generate a useful description out of it.*
Tadalafil-tablets-figure-3 (Tadalafil 4)
This document seems to be a table displaying the values of systolic blood pressure (BP) in mmHg over time, possibly in the context of an experiment or study. The values are influenced by the administration of different doses of tadalafil and doxazosin, as well as a placebo, at different times of the day. Without additional context or a clear layout of the table, it's difficult to provide a more specific summary.*
Tadalafil-tablets-figure-4 (Tadalafil 5)
This is a graph depicting the concentration of Tadalafil in plasma (in ug/L) over time (in hours) following the administration of a single 20-mg dose or a single 5-mg dose of the medication. It also shows the concentration of Tadalafil over time following once-daily 5-mg doses of the medication for five consecutive days. The X-axis represents time in hours, while the Y-axis represents the concentration of Tadalafil in ug/L.*
Table 5 (Tadalafil 6)
Table 6 (Tadalafil 7)
The text describes the change in the International Prostate Symptom Score (IPSS) total score between Tadalafil 5 mg and placebo. No other information is available.*
Tadalafil-tablets-figure-7 (Tadalafil 8)
Image 8 (Tadalafil 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
